Pharsight

Numbrino patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10016407 OMNIVIUM PHARMS Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US10973811 OMNIVIUM PHARMS Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US10894012 OMNIVIUM PHARMS Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US10857095 OMNIVIUM PHARMS Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US10420760 OMNIVIUM PHARMS Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US10413505 OMNIVIUM PHARMS Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US10149843 OMNIVIUM PHARMS Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US9867815 OMNIVIUM PHARMS Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US10933060 OMNIVIUM PHARMS Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US11040032 OMNIVIUM PHARMS Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US10231961 OMNIVIUM PHARMS Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

Numbrino is owned by Omnivium Pharms.

Numbrino contains Cocaine Hydrochloride.

Numbrino has a total of 11 drug patents out of which 0 drug patents have expired.

Numbrino was authorised for market use on 10 January, 2020.

Numbrino is available in solution;nasal dosage forms.

Numbrino can be used as a method for treating a subject with uveal melanoma with unresectable hepatic metastases, method of administering a local anesthetic to the mucous membranes, method of administering a local anesthetic to the mucous membranes in patients with renal impairment, method for the induction of local anesthesia prior to performing a procedure on, through, or adjacent to the mucous membranes, method of administering a local anesthetic prior to performing a diagnostic or surgical procedure on a subject with hepatic or renal impairment, method for the induction of local anesthesia of the mucous membranes.

Drug patent challenges can be filed against Numbrino from 14 December, 2021.

The generics of Numbrino are possible to be released after 07 February, 2037.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 14, 2022
New Product(NP) Jan 10, 2023

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using COCAINE HYDROCHLORIDE ingredient

NCE-1 date: 14 December, 2021

Market Authorisation Date: 10 January, 2020

Treatment: Method of administering a local anesthetic prior to performing a diagnostic or surgical procedure on a subject with hepatic or renal impairment; A method for treating a subject with uveal melanoma wit...

Dosage: SOLUTION;NASAL

More Information on Dosage

NUMBRINO family patents

Family Patents